Novartis’s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. The startup already has drug R&D alliances with BridgeBio Pharma, Merck, and Argenx.
The post Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets appeared first on MedCity News.
